More news: Health/Surgery
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Neurodegenerative Disorder Therapeutics Market Sees a Silver Lining with Cell and Gene Therapies Finds Frost & Sullivan - The market is expected to reach $15.44 billion by 2024 at a CAGR of 8.30% with improvements in early disease diagnosis, finds Frost & Sullivan - Frost.com
Neurodegenerative Disorder Therapeutics Market Sees a Silver Lining with Cell and Gene Therapies Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Santa Clara, CA, United States, 2019/10/28 - The market is expected to reach $15.44 billion by 2024 at a CAGR of 8.30% with improvements in early disease diagnosis, finds Frost & Sullivan - Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With both large pharmaceutical companies and mid-sized biotechs adopting emerging technologies such as artificial intelligence and machine learning, there has been a reorientation of drug discovery and development, validation, testing, and clinical deployment. Scientific advancements such as cell and gene therapies and understanding of the microbiome, plus improvements in early disease diagnostics, are expected to drive the $9.56 billion neurodegenerative disorder (ND) therapeutics market for Alzheimer’s and Parkinson’s Diseases (AD/PD) toward $15.44 billion in 2024 at a compound annual growth rate (CAGR) of 8.30%.

“With the alarming attrition rate of clinical pipeline for Alzheimer’s and Parkinson’s, and elusive success of therapies in their ability to modify disease, the future of the therapy hinges on the course of action companies take today,” said Khushbu Jain, Transformational Health Industry Analyst. “As the understanding of science behind disease deepens and offers new pathways for drug development, pharma companies will have to seek additional avenues for revenue and unconventional partnerships to offer immediate solutions to patients. The most lucrative partners remain digital platform providers that can help manage the disease better, help expedite drug discovery and, ultimately, deliver on outcome-based care.”

Frost & Sullivan’s recent analysis, Growth Opportunities in the Neurodegenerative Disorder Therapeutics Market, Forecast to 2024, examines the new risk mitigation strategies in light of generalization and price erosion. It also identifies viable partnership models and the organizations’ alternative solutions to R&D challenges cloaked in digital alternatives. It analyzes the innovativeness of the key regional markets of North America, Western Europe (EU5, Scandinavia, Benelux), and Asia-Pacific (China, Philippines, Indonesia, India, Malaysia, Singapore, Japan, Vietnam, South Korea, Taiwan, Australia, and Thailand).

“Unprecedented funding, favorable regulatory overhaul, and culture of open innovation will create a favorable environment for successful disease-modifying therapies, despite the high degree of drug pipeline attrition. The segments with the most potential will be cell and gene therapies,” noted Jain. “By 2024, adjunctive digital therapies are expected to become an integral part of care delivery for NDs.”

There will be additional growth opportunities for drug developers that:

• Invest in analytics platforms to reliably extract meaning from data gathered in uncontrolled environments, as well as establish the validity of patient-reported data.
• Focus on digital biomarkers as they offer an opportunity to go beyond episodic measurement to frequent and continuous symptom/outcome measurement.
• Utilize the microbiome to develop non-invasive diagnostic and screening tools to facilitate early detection, as related symptoms can serve as identifiable markers for PD diagnosis.
• Explore a combinatorial approach for AD, with stem cells tagged with neurotransmitters or protein-modifying enzymes, and simultaneously evaluate sources, types, stages, doses, and routes of stem cell transplantation for therapy optimization.
• Collaborate with device manufacturers from the early stages of drug discovery to design targeted drug delivery devices.
• Leverage new-generation digital tools or outsource them to contract research organizations (CROs) for faster, efficient, and economical repurposing of existing drugs.

Growth Opportunities in the Neurodegenerative Disorder Therapeutics Market, Forecast to 2024 is part of Frost & Sullivan’s global Life Sciences Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan (frost.com) has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Growth Opportunities in the Neurodegenerative Disorder Therapeutics Market, Forecast to 2024 / MECB-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Neurodegenerative Disorder Therapeutics Market Sees a Silver Lining with Cell and Gene Therapies Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Neurodegenerative | Frost & Sullivan
Contact: Mariana Fernandez - Frost.com 
210-348-1012 mariana.Fernandez[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

South Carolina’s Humimic Medical Arming Healthcare Workers for the COVID-19 War
SCBIO Executive Erin Ford Appointed to South Carolina District Export Council for 2020-2021
University of the Ryukyus and NEC Discover a Novel Diagnostic Biomarker for Acute Adult T-cell Leukemia/lymphoma
Change Healthcare Recognized by Frost & Sullivan for Accelerating Claims Processing with its Intelligent Healthcare Network™ Blockchain Technology
SCBIO CEO Sam Konduros Named to South Carolina Chamber Executive Committee
Frost & Sullivan Defines Top Femtech Global Opportunities by 2024
Frost & Sullivan Highlights on Impact of the Coronavirus on Business
Global Healthcare to Soar Above Trillion in 2020 with Consumerism and Outcome-based Care Models Finds Frost & Sullivan
Demand for CROs Rises to Strike Evolving Clinical Trial Models for Target Therapies Reports Frost & Sullivan
PointClickCare Integrated Care Coordination Platform Applauded by Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today